Pfizer Launches Phase II Trial For Experimental Glaucoma Treatment In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer will expand the clinical development program for its experimental glaucoma treatment PF-03187207 by launching a Phase II trial in Japan, French partner NicOx announced Jan. 3